35306-74-2

Usage

Uses

Used in Pharmaceutical Research:
3-Bromo-N-propylbenzamide is used as a building block for the development of more complex molecules in pharmaceutical research. Its unique structure and biological activities make it a valuable component in the creation of new drugs and therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, 3-Bromo-N-propylbenzamide is used as a starting material for the synthesis of various organic compounds. Its reactivity and functional groups allow for further chemical modifications and the formation of new molecules with potential applications in different industries.
Used in Drug Development:
3-Bromo-N-propylbenzamide is used as a potential candidate for drug development due to its biological activities. Researchers are interested in exploring its potential as a therapeutic agent for various diseases and conditions, leveraging its chemical properties to design effective and targeted treatments.
Used in Medicinal Chemistry Research:
In medicinal chemistry research, 3-Bromo-N-propylbenzamide is employed as a subject of study to understand its interactions with biological targets and its potential as a lead compound for the development of new pharmaceuticals. Its unique structure and properties make it an interesting subject for researchers to investigate its therapeutic potential and optimize its properties for specific applications.

InChI:InChI=1/C10H12BrNO/c1-2-6-12-10(13)8-4-3-5-9(11)7-8/h3-5,7H,2,6H2,1H3,(H,12,13)

Upstream product

• 107-10-8 propylamine 
• 1711-09-7 3-bromobenzoyl chloride 
• 585-76-2 m-bromobenzoic acid 

Downstream Products

• 873327-95-8 (R)-3-(benzylthio)-2-(3-(biphenylcarbonyl)-3-propylureido)propanoic acid 
• 873328-63-3 C₂₆H₂₈N₂O₂S 
• 1034733-96-4 C₂₁H₁₈ClNO₂ 
• 1034733-95-3 C₂₁H₁₈ClNO₂ 
• 873331-17-0 3-(naphthalen-2-yl)-N-propylbenzamide 
• 873329-56-7 3-(naphthalen-1-yl)-N-propylbenzamide 
• 65261-07-6 N-n-Propyl-3-phenoxybenzamid 

Relevant academic research and scientific papers

Rhodium(III)-Catalyzed Redox-Neutral Coupling of α-Trifluoromethylacrylic Acid with Benzamides through Directed C?H Bond Cleavage

A rhodium(III)-catalyzed redox-neutral coupling of α-trifluoromethylacrylic acid with bezamides proceeds smoothly accompanied by amide-directed C?H bond cleavage to produce β-[2-(aminocarbonyl)phenyl]-α-trifluoromethylpropanoic acid derivatives. One of th

De-novo designed library of benzoylureas as inhibitors of BCL-X L: Synthesis, structural and biochemical characterization

The prosurvival BCL-2 proteins are attractive yet challenging targets for medicinal chemists. Their involvement in the initiation and progression of many, if not all, tumors makes them prime targets for developing new anticancer therapies. We present our approach based on de novo structure-based drug design. Using known structural information from complexes engaging opposing members of the BCL-2 family of proteins, we designed peptidomimetic compounds using a benzoylurea scaffold to reproduce key interactions between these proteins. A library stemming from the initial de novo designed scaffold led to the discovery of ligands with low micromolar potency (KD = 4 μM) and selectivity for BCL-XL. These compounds bind in the canonical BH3 binding groove in a binding mode distinct from previously known BCL-2 inhibitors. The results of our study provide insight into the design of a new class of antagonists targeting a challenging class of protein-protein interactions.

Alpha-helical mimetics

Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

AMINO-5-[4-(DIFLUOROMETHOXY)-PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE

The present invention provides a 2-amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

ALPHA-HELICAL MIMETICS

Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralising pro-survival Bcl-2 proteins. Use of the benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also disclosed.